CA-RECOVER
Three leading companies in the textiles industry, Recover™, Happy Punt, and Hansae, have entered into a multi-year partnership agreement to provide end-to-end solutions for the design, development, and production of sustainably conscious apparel for the fashion industry. The partnership allows retailers and brands to seamlessly integrate sustainable Recover™ recycled cotton fiber into their products, thereby helping to solve one of the world’s biggest environmental issues.
Using innovative technology, the partnership provides a range of services, including 3D design, patterns, tech packs, samples, and production to support brands and retailers at every step in the supply chain. The partnership offers a unique speed to market solution for the production of fully sustainable apparel and leverages the group’s global reach, with offices in Seoul, Barcelona, and New York. In addition, close customer proximity provides in-market technical design services that develop, review and approve all specifications to ensure correct fit and brand enhancing products.The partnership also provides an end-to-end service that combines the advantages of production nearshore and offshore worldwide.
Dedicated leading edge design and development facilities can produce samples in house from concept to finished sample with a quick turnaround time. Notably, as part of a joint sustainability initiative, the partnership also encourages R&D designs to be replaced by 3D designs to reduce the environmental impact of the sampling process.
The three leading companies have a combined experience of over 130 years in each of their respective fields. Each firm’s commitment to bringing the best technology to the product and the market offers a disruptive approach to the traditional apparel design and production process. The partnership is proud to be actively working with leading global brands to deliver sustainable collections to the market by Spring 2022, and more collections are expected to follow.
Recover™ will increase its production to 200,000 metric tons of recycled cotton fiber per year by 2025 to support the current market demand. This recycled cotton volume will save nearly three trillion liters of water each year, equivalent to the drinking water consumed by 3 billion people on an annual basis and allow 500,000 acres of land to be directed away from cotton cultivation to other uses.
The Recover™, Happy Punt, and Hansae strategic partnership provides brands and retailers with an easy plug & play solution to achieve their sustainability initiatives and ensures a quality product for the consumer.
About Recover™
Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.
As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
For more information, visit www.recovertex.com and follow @recoverfiber on social media.
About Happy Punt
Happy Punt is a design and manufacturing end-to-end solution provider to the fashion industry, applying virtual design tools supported by the best technology offering an efficient and sustainable product development and design process. Founded in 1996, Happy Punt has more than 25 years of history in the fashion business, and a team of 80 fashion designers and PD&D. Happy Punt offers a “Gold Standard” of excellence in technical and production know-how that ensures the manufacturing and delivery of safe and reliable products by providing a global end-to-end service recognized for the quality of their fashion design and for the speed of their creative process.
About Hansae
Established in 1982, Hansae Co., Ltd. has maintained consistent growth through specialized apparel exports and annually produces over 300 million garments. Hansae has 14 global corporations in 7 countries, over 600 people at the corporate Headquarters, and over 35,000 in the global manufacturing workforce.
Its mission is to enrich customer’s lives and lead fashion culture by providing the best quality clothes at a reasonable price. Quality management systems maximize values for its customers by ensuring manufacturing excellence and on-time, safe delivery of products.
Hansae has developed HAMS, its own smart factory system to maximize the efficiency of production plants in Vietnam, Indonesia, Myanmar, Nicaragua, Guatemala, and Haiti.
Hansae aims to be a front-runner in sustainable management by establishing ‘10% For Good’, pledging to donate 10 percent of its net profits from sustainable orders to third parties that work toward improving ocean environment by collecting wastes, the advancement of green raw materials, and hardware upgrades and retrofits.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005776/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom